Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 522,707,776
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • 60-Month Beta 0.42
  • Price/Sales 15.71
  • Price/Cash Flow 39.55
  • Price/Book 32.91
Trade NVO with:

Options Overview Details

View History
  • Implied Volatility 33.24% ( +1.95%)
  • Historical Volatility 31.23%
  • IV Percentile 71%
  • IV Rank 38.52%
  • IV High 49.01% on 08/05/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 1.09
  • Today's Volume 4,575
  • Volume Avg (30-Day) 21,017
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 263,524
  • Open Int (30-Day) 258,445

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.91
  • Number of Estimates 3
  • High Estimate 0.97
  • Low Estimate 0.87
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +24.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
115.40 +0.30%
on 10/02/24
138.22 -16.26%
on 09/16/24
-20.51 (-15.05%)
since 09/03/24
3-Month
115.40 +0.30%
on 10/02/24
143.69 -19.44%
on 07/08/24
-23.12 (-16.65%)
since 07/03/24
52-Week
87.02 +33.02%
on 10/05/23
148.15 -21.87%
on 06/25/24
+27.97 (+31.86%)
since 10/03/23

Most Recent Stories

More News
3 Momentum Trades Too Good Pass Up

Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going.

INTC : 22.38 (-0.04%)
NVO : 115.71 (-0.66%)
LLY : 886.30 (-0.54%)
SPY : 567.79 (-0.19%)
ISRG : 480.64 (-1.23%)
DELL : 114.64 (+1.04%)
MTUM.BZ : N/A (N/A)
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie’s...

NVO : 115.71 (-0.66%)
GMAB : 23.42 (-1.14%)
LLY : 886.30 (-0.54%)
ABBV : 195.94 (-0.45%)
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors

Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics.Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation...

NVO : 115.71 (-0.66%)
LLY : 886.30 (-0.54%)
NVS : 114.02 (-0.39%)
RHHBY : 38.4800 (-1.51%)
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition

NetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug...

ANVS : 8.14 (-2.63%)
NVO : 115.71 (-0.66%)
LLY : 886.30 (-0.54%)
ABBV : 195.94 (-0.45%)
PFE : 28.30 (-1.08%)
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition

EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END

ANVS : 8.14 (-2.63%)
NVO : 115.71 (-0.66%)
LLY : 886.30 (-0.54%)
ABBV : 195.94 (-0.45%)
PFE : 28.30 (-1.08%)
This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

NVO : 115.71 (-0.66%)
MS : 103.53 (-0.95%)
LLY : 886.30 (-0.54%)
GPCR : 42.10 (-3.20%)
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years

These two players are set on finding the next big therapeutic modality.

NVO : 115.71 (-0.66%)
LLY : 886.30 (-0.54%)
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?

The thrust of the company's long-term strategy is becoming clearer.

NVO : 115.71 (-0.66%)
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead

Even the mighty Novo Nordisk can't hold a candle to its peer in this area.

NVO : 115.71 (-0.66%)
ABBV : 195.94 (-0.45%)
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.

The healthcare company's pivot into a new set of technologies will have many implications for the stock.

NVO : 115.71 (-0.66%)
LLY : 886.30 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 118.44
2nd Resistance Point 117.61
1st Resistance Point 117.05
Last Price 115.71
1st Support Level 115.66
2nd Support Level 114.83
3rd Support Level 114.27

See More

52-Week High 148.15
Fibonacci 61.8% 124.80
Fibonacci 50% 117.58
Last Price 115.71
Fibonacci 38.2% 110.37
52-Week Low 87.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar